A San Diego-based biopharmaceutical company that has built a $2.83 billion commercial franchise around neurological and endocrine disorders, anchored by INGREZZA in tardive dyskinesia and the first new CAH treatment in roughly seven decades.
A San Diego-based biopharmaceutical company that has built a $2.83 billion commercial franchise around neurological and endocrine disorders, anchored by INGREZZA in tardive dyskinesia and the first new CAH treatment in roughly seven decades.
